Next Article in Journal
Advances in the Management of Metastatic Breast Cancer: Options Beyond First-Line Chemotherapy
Previous Article in Journal
Accelerating Knowledge to Action: The Pan-Canadian Cancer Control Strategy
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 2
10.3747/co.19.1018
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada

by
V. Hirsh
1,2,3,*,
B. Melosky
4,
G. Goss
5,
D. Morris
6 and
W. Morzycki
7
1
Hematology–Oncology Services, Santa Cabrini Hospital, Montreal, QC, Canada
2
Oncology Services, Royal Victoria Hospital and Montreal General Hospital, Montreal, QC, Canada
3
Department of Oncology, Faculty of Medicine, McGill University, Montreal, QC, Canada
4
BC Cancer Agency and University of British Columbia, Vancouver, BC, Canada
5
The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada
6
Tom Baker Cancer Centre and University of Calgary, Calgary, AB, Canada
7
Cancer Care Nova Scotia and Dalhousie University, Halifax, NS, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(2), 78-90; https://doi.org/10.3747/co.19.1018
Submission received: 6 March 2012 / Revised: 7 March 2012 / Accepted: 13 March 2012 / Published: 1 April 2012

Abstract

Lung cancer is one of the most commonly diagnosed malignancies and the leading cause of cancer-related mortality in Canada. The heterogeneity of nsclc and the importance of linking new targeted agents to the appropriate disease subtype require an individualized approach to treatment. In patients with EGFR (epidermal growth factor receptor gene) mutations, egfr tyrosine kinase inhibitors (tkis) provide a highly effective treatment option, with improved toxicity compared with standard chemotherapy. However, the identification of mutation-positive patients is limited by a lack of funding for testing. The length of time required to receive test results and insufficient tissue from biopsies are additional limitations. In Canada, the use of egfr-tkis varies based on differences in provincial funding for both testing and treatment. With improvements in testing and access to funding for treatment, targeted use of egfr-tkis may greatly improve outcomes in nsclc.
Keywords: nsclc; egfr; egfr-tkis; Canadian situation nsclc; egfr; egfr-tkis; Canadian situation

Share and Cite

MDPI and ACS Style

Hirsh, V.; Melosky, B.; Goss, G.; Morris, D.; Morzycki, W. A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Curr. Oncol. 2012, 19, 78-90. https://doi.org/10.3747/co.19.1018

AMA Style

Hirsh V, Melosky B, Goss G, Morris D, Morzycki W. A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology. 2012; 19(2):78-90. https://doi.org/10.3747/co.19.1018

Chicago/Turabian Style

Hirsh, V., B. Melosky, G. Goss, D. Morris, and W. Morzycki. 2012. "A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada" Current Oncology 19, no. 2: 78-90. https://doi.org/10.3747/co.19.1018

APA Style

Hirsh, V., Melosky, B., Goss, G., Morris, D., & Morzycki, W. (2012). A Personalized Approach to Treatment: Use of egfr Tyrosine Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer in Canada. Current Oncology, 19(2), 78-90. https://doi.org/10.3747/co.19.1018

Article Metrics

Back to TopTop